Form 4: Katherine A. High Acquires 13,000 CRISPR Therapeutics Stock Options
SEC Form 4 Filing
Director Katherine A. High acquired 13,000 stock options in CRISPR Therapeutics AG on May 30, 2024.
Summary
- Katherine A. High, a director of CRISPR Therapeutics AG, reported a transaction involving derivative securities.
- On May 30, 2024, Ms. High acquired 13,000 stock options with an exercise price of $54.06.
- These options grant the right to buy 13,000 common shares of CRISPR Therapeutics.
- The options vest in 12 equal monthly installments starting May 31, 2024, with the final installment vesting no later than the 2025 Annual General Meeting of Shareholders.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future.
Key Dates
| Date | Description |
|---|---|
| 05/30/2024 | Date of transaction: Katherine A. High acquired 13,000 stock options. |
| 05/31/2024 | First vesting date for the stock options. |
| 05/30/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.